DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
e•••••• I••
Drug Discovery & Developmentgroup grade Bon a schedule nowsponsor unattributed
Also written as: and enGene Inc; Inc. and
What matters now
- 100¢ → 103¢consensus mark
Consensus mark 103¢ on cost, up from 100¢ a year ago, 101¢ last quarter.
Q1 2026 · The lenders' own valuations moved back up.
Derived1 of 1 lender' own marks, weighted by principal
Mark path, consensus per quarter end
100¢ · 100¢ · 101¢ · 101¢ · 103¢Q1 2025 to Q1 2026
Principal held
at least $17.5M
sum of BDC pieces, a lower bound
Fair value
$18.4M
103c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
2 equity pieces beside them
Next maturity
Jan 1, 2030
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Mar 31, 2026
Events
6
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $17.5M | 103¢ | +2 pts |
Every BDC piece · 3 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, J•••••• 2030, P•••• + 2.25%, F•••• rate 9.25%, Cap rate 10.25%, 5.95% E••• | $17.5M | $18.3M 103c | S+225 bp |
| H••••••• C••••••• I••• | warrants equity W••••••, 12/22/2023, C••••• S•••• | Not disclosed | $151,000 69c | |
| H••••••• C••••••• I••• | warrants equity W••••••, A••••••••• D••• 12/22/2023, Series C••••• S•••• | Not disclosed | Not disclosed |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Mar 31, 2026 | at least $17.5M | 103c | S+225 bp | Jan 1, 2030 | 1 |
Equity pieces beside the debt: preferred equity ($0 fair value, 1 BDC), warrants ($151,000 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2026 | 1 | $17.5M | $18.3M | 103c | 0 |
| Dec 31, 2025 | 1 | $32.2M | $33.3M | 101c | 2 |
| Sep 30, 2025 | 1 | $16.1M | $16.6M | 101c | 1 |
| Jun 30, 2025 | 1 | $16.0M | $16.3M | 100c | 1 |
All 14 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2025 | 1 | $16.0M | $16.2M | 100c | 1 |
| Dec 31, 2024 | 1 | $31.8M | $32.3M | 101c | 2 |
| Sep 30, 2024 | 1 | $15.9M | $16.3M | 103c | 1 |
| Jun 30, 2024 | 1 | $15.8M | $15.9M | 101c | 1 |
| Mar 31, 2024 | 1 | $15.8M | $16.0M | 102c | 1 |
| Dec 31, 2023 | 1 | $47.3M | $46.6M | 100c | 3 |
| Sep 30, 2023 | 1 | $9.8M | $10.2M | 101c | 0 |
| Jun 30, 2023 | 1 | $11.0M | $11.3M | 100c | 0 |
| Mar 31, 2023 | 1 | $11.0M | $11.1M | 100c | 0 |
| Dec 31, 2022 | 1 | $11.0M | $11.1M | 100c | 0 |
What changed
- Maturity extended (observed)Mar 31, 2026
- Facility left every BDC scheduleMar 31, 2026
- Spread changed (observed)Mar 31, 2026
- Spread increasedMar 31, 2026
- Maturity extended (observed)Mar 31, 2026
Full timeline · 10 eventsShow fewer
- PIK interest appearsDec 31, 2023
- Spread changed (observed)Dec 31, 2023
- Maturity extended (observed)Dec 31, 2023
- PIK interest appearsDec 31, 2023
- Maturity extended (observed)Dec 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- ENGENEderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it